Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

We identified a group of miRNA genes whose methylation is associated with ovarian cancer metastasis. Based on these data, new markers and the systems of markers predicting tumor dissemination were selected. Using methylation-specific PCR and a representative set of 54 ovarian cancer samples, we identified 10 microRNA genes (MIR-124a-2, MIR-127, MIR-125b-1, MIR-129-2, MIR-137, MIR-193a, MIR-203a, MIR-34b/c, MIR-130b, and MIR-1258) whose methylation is associated with tumor metastasis. The greatest association was established for 4 genes: MIR-137, MIR-193a, MIR-34b/c, and MIR-130b (p<0.01). ROC analysis revealed 3 most optimal marker systems including 4-5 miRNA genes and characterized by high sensitivity (82-94%) and specificity (76-86%) at AUC=0.89-0.92. Methylation of any three genes from these systems is sufficient to predict metastasis with the specified accuracy. Detection of the group of hypermethylated miRNA genes with predictive value for ovarian cancer metastasis is of great importance for personalized treatment of the patients.

Авторлар туралы

E. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Ресей, Moscow

V. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Email: eleonora10_45@mail.ru
Ресей, Moscow; Moscow

A. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Ресей, Moscow

E. Braga

Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics

Хат алмасуға жауапты Автор.
Email: eleonora10_45@mail.ru
Ресей, Moscow; Moscow

I. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Ресей, Moscow

T. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Ресей, Moscow

D. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Ресей, Moscow

D. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Ресей, Moscow

M. Fridman

N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: eleonora10_45@mail.ru
Ресей, Moscow

D. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia

Email: eleonora10_45@mail.ru
Ресей, Moscow

N. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Ресей, Moscow


© Springer Science+Business Media, LLC, part of Springer Nature, 2019

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>